Afrezza (INHALE-1)

This study evaluates the safety and effectiveness of an inhaled short-acting insulin in children.
Clinical Description:
This study is evaluating the efficacy and safety of Afrezza, an inhaled insulin, in combination with a basal insulin versus insulin aspart or insulin lispro in combination with a basal insulin in pediatric subjects with type 1 or type 2 diabetes mellitus.
Target Age/Sex:
Over 4 years and under 18, Male & Female (on multiple daily injections)
Participants will receive at no cost: study product, study materials and study-specific procedures.
Study Length:
About 56 Weeks
Information Request

Information Request

To request additional information please call 208-522-6005 or email or complete the form below.